The popularity of Viagra initially drove a surge for pharma, nevertheless recent changes present a uncertain scenario for investors. Generic versions are reducing revenue, and continued litigation add additional risk https://iwandreg268793.blue-blogs.com/49370066/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment